GLP-1 Medications

Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD Yes—early research shows GLP-1 medications like semaglutide and tirzepatide may reduce cravings and reward-driven behaviors related to alcohol and other substances. However, they are not FDA-approved for addiction, and evidence varies by substance and study type.¹ How GLP-1 Medications Affect Addiction (Brain and Dopamine Explained) GLP-1 medications may influence addiction by modulating r

A physician-written review of the STEP 9 trial explaining how semaglutide improves knee osteoarthritis pain, how weight-loss milestones relate to knee replacement risk, and what this means for patients in Utah.

s taking GLP-1 medications every other week a good idea? Discover what 2025 pharmacologic models and clinical trials actually say about bi-weekly dosing, the risk of weight regain, and why consistent weekly treatment remains the gold standard for metabolic health.

A physician-written guide to alcohol use on GLP-1 medications like Ozempic®, Wegovy®, Mounjaro®, and Zepbound®. Covers GI side effects, blood sugar risk, altered tolerance, and emerging research on cravings.

"GLP-1 microdosing" is a popular, patient-driven trend for medications like semaglutide and tirzepatide. Understand the clinical reality behind sub-therapeutic doses, split dosing, and weight maintenance strategies.

"Ozempic Face" is trending, but is it the medication or the weight loss causing the change? Dr. Silva separates the myths from the massive weight loss science, explains why some patients look "gaunt" while others don't, and reviews which treatments actually restore facial volume.

Is it safe to breastfeed while taking Ozempic® or Mounjaro®? While limited data suggests low transfer into breast milk, official FDA guidance remains cautious due to unknown long-term risks. Learn about the science of peptide transfer, washout periods, and why most clinicians recommend discontinuing GLP-1s during lactation.

Experiencing sulfur burps or a "stuck" feeling on Ozempic? Dr. Joshua Silva, MD explains the science of delayed gastric emptying and offers 6 actionable tips to reduce gas and bloating.

Retatrutide is an investigational weight-loss medication often described as a “GLP-3.” This article explains what it is, how it works, how it compares to semaglutide and tirzepatide, safety considerations, FDA status, and whether patients should wait or start treatment now.

A physician-written guide explaining who should avoid or use caution with GLP-1 and GLP-1/GIP weight-loss medications like semaglutide and tirzepatide.

Older adults enjoying the benefits of weight loss and eating healthy while using GLP-1 medications (semaglutide or tirzepatide) for safe weight loss, heart health, and muscle and bone support.

What GLP-1/GIP medications really do for inflammation — and what they don’t. A clear, evidence-based guide for patients.

Semaglutide and tirzepatide can significantly improve insulin resistance, hormones, and weight in women with PCOS. Learn what clinical research shows—and whether these medications may be right for you.

If you’re comparing Zepbound (tirzepatide, GLP-1/GIP) vs. Wegovy (semaglutide, GLP-1) for weight loss, you’re not alone. These two medications are the most effective weight-loss injections available today — and both can help you lose significant weight safely under physician supervision. This guide breaks down how each medication works, how they differ, which one produces more weight loss, what side effects to expect, and how to choose the option that fits your goals, bud

Oral semaglutide (Wegovy® tablets) is now FDA-approved for chronic weight management. This once-daily 25 mg pill uses the same active ingredient as injectable Wegovy®, offering a needle-free option for patients who can’t tolerate injections or prefer a daily tablet. Learn how it works, how it compares to Wegovy® injections, and what this new approval means for access, dosing, and real-world weight-loss results.

Wegovy (semaglutide) is now FDA-approved for MASH with fibrosis (F2–F3) in adults. See what this means for treatment, eligibility, and weight management.

Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD As of 2026, compounded semaglutide and tirzepatide are no longer broadly permitted in the United States. Following resolution of nationwide shortages, the FDA ended its temporary enforcement discretion, meaning these medications may now only be compounded under limited, legally defined circumstances .¹–³ On February 21, 2025 , the U.S. Food and Drug Administration formally declared the

Wegovy (semaglutide) is FDA-approved to reduce major heart risks in adults with obesity/overweight and cardiovascular disease. Learn what it means and who qualifies.